National Cancer Institute

C-Path names Martha Brumfield as CEO

Tuesday, February 26, 2013 11:58 AM

The board of directors of the Critical Path Institute (C-Path), an independent, nonprofit organization, have named Martha Brumfield, Ph.D., as interim president and CEO. Brumfield, C-Path’s former director of international and regulatory programs, will take over immediately for Carolyn Compton, M.D., Ph.D. who will be assuming a new position at Arizona State University (ASU).

More... »

Lentigen receives Orphan Drug status for gene therapy for glioblastoma multiforme

Thursday, February 14, 2013 08:00 AM

Lentigen, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery products, announced that that the FDA has granted orphan drug status to LG631-CD34, P140K methylguanine methyltransferase (MGMT) transduced human CD34 cells, for bone marrow protection in the treatment of glioblastoma multiforme.

More... »

FDA approves Gleevec for children with acute lymphoblastic leukemia

Monday, January 28, 2013 11:22 AM

The FDA has approved a new use for Novartis’ Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).

More... »

CDISC names additions to board of directors

Friday, January 25, 2013 12:27 PM

CDISC, a global, open, non-profit organization that has established standards to support the acquisition, exchange, submission and archive of clinical research data and metadata, has named five highly qualified individuals that will add invaluable expertise to the CDISC board of directors (BoD) for a three-year term beginning this month (2013–2016): Dr. Carolyn Compton, Michael Glickman, Dr. Douglas Peddicord, Stephen Pyke and John Speakman.

More... »

C-Path and CDISC launch CFAST

Friday, September 14, 2012 12:35 PM

The Clinical Data Interchange Standards Consortium (CDISC), a global non-profit charitable organization, and Critical Path Institute (C-Path), a Tucson, Ariz.-based non-profit organization committed to improving human health and well-being, have launched their joint Coalition For Accelerating Standards and Therapies (CFAST), a follow-up to the partnership agreement signed earlier this year.

More... »

Recipients of 2012 SAFE-Biopharma Digi Award named

Monday, April 30, 2012 04:52 PM

Recipients have been selected for the 2012 SAFE-BioPharma Digi Award, recognizing innovative uses of the global SAFE-BioPharma digital identity and digital signature standard and the institutions and individuals contributing to broader understanding of its benefits. Recipients included: Astellas, Bristol-Myers Squibb and representatives of two U.S. government entities.

More... »

Syndax initiates phase I/II study in metastatic breast cancer

Monday, April 9, 2012 04:42 PM

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company based in Waltham, Mass., has initiated a phase I/II study combining its lead product entinostat with lapatinib ditosylate (Tykerb) in patients with locally recurrent or distant relapsed metastatic breast cancer previously treated with trastuzumab (Herceptin).

More... »

SAFE-BioPharma named Computerworld Laureate

Monday, March 26, 2012 03:49 PM

SAFE-BioPharma, the global digital identity and digital signature standard for the life sciences and healthcare sectors, has been named a 2012 Computerworld Laureate.

More... »

Celtic launches $50 million antibody drug conjugates company

Monday, March 26, 2012 12:19 PM

Celtic Therapeutics Management, a global private equity firm focused on novel therapeutic product candidates, has announced a significant commitment to Antibody-Drug-Conjugate (ADC) products with the launch of a new Lausanne, Switzerland-based company, ADC Therapeutics Sarl.

More... »

Metabolomx awarded $1.14 million grant from NCI

Monday, October 24, 2011 01:34 PM

Metabolomx, a diagnostic company focused on breath analysis for the detection of cancer, has been awarded a Small Business Innovation Research (SBIR) contract by the National Cancer Institute (NCI). The $1.14 million combined phase I/II Fast-Track contract will support the research and development of Metabolomx' sensor array system to detect lung cancer.

More... »